<DOC>
	<DOCNO>NCT02185768</DOCNO>
	<brief_summary>The frequently use product CHE doxorubicin ( 36 % ) , cisplatin ( 31 % ) , epirubicin ( 12 % ) . But recently , obvious reason use one product another . In fact , systemic chemotherapy consider ineffective HCC [ hepatocellular carcinoma ] , allow argument favour product . Moreover , 2 randomised trial compare molecule ( doxorubicin vs. epirubicin ) prove negative term survival . Cytotoxicity different anticancer agent HCC cell line compare order select best candidate CHE . Eleven chemotherapy molecule test , include frequently use CHE . Among , idarubicin ( anthracycline ) prove effective vitro far . The superiority idarubicin ( opposed doxorubicin ) note especially SNU-449 line , know resistance several chemotherapy agent . The best cytotoxicity idarubicin explain 2 mechanism : 1 ) idarubicin well intracellular penetration anthracyclines . This probably due considerable lipophily , facilitate thus passage membrane make double lipid layer , 2 ) idarubicin resistant multidrug resistance system ( MDR ) . The MDR mechanism , often note HCC , consist membrane pump transport molecule outside cell . These two particularity could explain significant accumulation idarubicin HCC cell , thus good efficacy . It interesting note orally administer idarubicin ( 5 mg/day 21 day ) prove less toxic effective HCC . Currently , idarubicin use treat leukaemia . Its toxicity profile ( especially , haematological cardiac ) know . On ground , A pilot study conduct order ass tolerance efficacy lipiodol-based CHE use 10 mg dose idarubicin 21 patient unresectable HCC . These preliminary data reveal CHE idarubicin effective less toxic . Idarubicin load microbeads . A phase I study ( IDASPHERE ) conduct DC Beads® microbeads ( 300-500µm ) load idarubicin ( dose increase 5 25 mg ) . The DLT [ dose-limiting toxicity ] MTD [ maximum tolerate dose ] determine 21 patient use CRM . The MTD idarubicin assess 10 mg . In study , idarubicin-loaded bead give rise specific toxicity-related problem . The 10 mg dose compatible know toxicity profile idarubicin : cumulative cardiotoxicity doxorubicin note 550 mg/m² , whereas idarubicin note 93 mg/m² . There thus 5.9:1 ratio cumulative toxicity . The frequently use dose ( also weakest one ) doxorubicin-based CHE 50 mg . The equivalent idarubicin dose would thus : 50 mg ( doxorubicin ) / 5.9 ( doxorubicin/idarubicin ratio ) = approx . 10 mg idarubicin . It already demonstrate hepatic extraction idarubicin well doxorubicin daunorubicin animal sarcoma model . In study , AUC 0-48h AUC 0-72h 1.35 time higher idarubicin , prove intra-hepatic penetration 35 % high . The randomised phase II PRECISION V study compare conventional CHE ( cCHE ) CHE doxorubicin bead ( DC Bead® ) patient HCC . It currently large randomise trial CHE publish . The PRECISION V data thus use compare study term efficacy tolerance . To continue preliminary study phase I IDASPHERE study , investigator wish assess thus efficacy confirm tolerance idarubicin-loaded bead CHE HCC accord protocol similar PRECISION V , part single-arm phase II study .</brief_summary>
	<brief_title>Chemoembolisation Hepatocellular Carcinomas Not Subject Interventive Care Idarubicin-loaded Beads - IDASPHERE II</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Histologically diagnose HCC HCC diagnose accord EASL criterion Measurable target accord mRECIST v1.1 criterion Preserved liver function ( case ChildPugh A B7 cirrhosis ) Tumour subject interventive care ( liver transplant , surgical resection percutaneous destruction ) BCLC A/B without portal extrahepatic invasion No prior treatment chemotherapy , radiotherapy transarterial embolisation ( without chemotherapy ) Age ≥ 18 year WHO 0 1 Laboratory test : platelet ≥ 50,000 mm3 , N ≥ 1,000/mm3 , creatininaemia ≤ 150 µmol/L , PT ≥ 50 % No heart failure ( isotope ultrasound VEF &gt; 50 % ) Advanced tumour ( vascular extrahepatic invasion include brain metastasis diffuse HCC liver invasion &gt; 50 % ) History type cancer except cancer know remission 5 year ( case , HCC histological proof require ) , basalcell carcinoma situ cervix uteri cancer properly treat curative treatment Advanced liver disease ( Child B8 , B9 C , bilirubinaemia &gt; 3 mg/dL , SGOT SGPT &gt; 5 x ULN 250 U/L ) Previous treatment idarubicin and/or doxorubicin Idarubicin contraindication ( cardiopathy myocardial failure , serious kidney liver failure , yellow fever vaccine ) Concurrent disease uncontrolled severe clinical condition Uncontrolled severe infection Patient require longterm anticoagulant treatment Thrombosis portal vein 3segment region Hepatofugal portal venous flow Presence serious atheromatosis Presence collateral vascular way potentially affect normal region embolisation Presence arthritis hepatic artery branch treat Presence arterioportal arterial subhepatic fistula embolised coil Pregnancy breastfeed Absence effective contraception ( men woman childbearing age ) Patient regularly monitor account psychological , social , family geographyrelated reason Concomitant participation patient another study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Liver cancer</keyword>
</DOC>